What is detransition?
Detransition is the process by which someone wholly or partially reverses a previously initiated gender transition. This may involve social, medical or legal steps. Detransition has long been dismissed as a marginal phenomenon, but recent research and the growing number of people sharing their stories show that it concerns a substantial and underrepresented group. Those who detransition generally face the consequences of treatments that are partly or wholly irreversible — often without an appropriate care pathway for returning.
What does detransition involve?
Detransition takes place on several levels. On a social level, someone returns to their original name, pronouns and gender expression. On a medical level, hormone therapy is stopped and, where anatomically possible, attempts are sometimes made to reverse surgical procedures. On a legal level, the registered sex designation is changed again.
The three levels do not progress in parallel. Social detransition is relatively straightforward, medical detransition is limited by what the body allows, and legal detransition is administratively burdensome. In practice, those who have progressed far along the medical pathway can no longer return to their starting point: their voice, fertility, breast tissue and genitals have been permanently altered or lost as a result of hormones and surgery.
Why do people detransition?
The reasons for detransition are increasingly being documented. In the self-reported study by Vandenbussche (2021) involving 237 detransitioners, respondents mentioned, among other things: realizing that their dysphoria was connected to other issues (trauma, internalized misogyny, autism, eating disorders and homophobia), inadequate psychological screening, social pressure from online communities, and disappointment with the outcomes of treatment. In a separate detransition survey, Littman (2021) reported a similar pattern, with respondents also frequently noting that healthcare providers had not asked enough questions before a medical pathway was started. The DARE study from 2026, with 957 participants the largest survey to date, confirms that stopping treatment rarely has a single cause. More about the findings of these surveys can be found under detransitioners' experiences.
A recurring theme in these accounts is that transition was presented as a solution to a deeper problem — while it later became clear that dysphoria and discomfort with the body can also have other causes. Another recurring theme is that some care pathways left little room for refraining from treatment or expressing doubt. The gender-affirmative model takes self-identification as its guiding principle; as a result, differential diagnosis is pushed into the background.
Detransition and regret
Detransition and transition regret are not identical, but they overlap more than mainstream discourse acknowledges. For a long time, official figures focused almost exclusively on people who formally reported regret to the treating clinic — a high threshold that severely underestimated the true scale. Those who seek care elsewhere, or drop out altogether, are not included in these figures.
See also the page on detransition figures for an overview of what the research shows so far — and why these figures are probably a lower bound.
The healthcare system and detransition
Detransitioners run up against a healthcare system designed for transition, not for returning. In the Netherlands, there are no specialized clinics for the medical consequences — endocrine disruption, reconstructive needs and fertility loss. The same applies to the psychological consequences: mainstream mental healthcare rarely has experience with this specific issue, and specialized transgender care is institutionally connected to promoting transition, not supporting detransition. Practical guidance can be found under support after detransition. In the United States, such care has been mandated for the first time: following a ten-million-dollar settlement with the Texas attorney general, Texas Children's Hospital must open the country's first detransition clinic within three months.
The Cass Review (United Kingdom, 2024) explicitly noted that the evidence base underpinning current gender-affirmative care for young people is weak and that detransition is systematically inadequately monitored. Cass recommends that detransitioners receive recognized, non-stigmatizing aftercare — a recommendation that has so far barely been translated into practice in the Netherlands.
Recognition and having a voice
Many detransitioners describe how their experiences are minimized or dismissed as anecdotal within the trans community and by activist organizations. In the Netherlands, transspijt.nl provides a platform for personal accounts. Internationally, Genspect collects testimonies and advocates for better care. An overview of online communities can be found under detransition platforms. Those who listen hear recurring patterns: that treatment was initiated too easily, that alternative explanations for suffering were not investigated, and that there was little room to voice doubts openly.
Taking detransition seriously does not mean denying dysphoria or claiming that transition is always wrong. It does mean that the care model must be critically examined — and that the people for whom treatment had harmful consequences must be heard, treated and not pushed out of sight.